Skip to main content
Fig. 2 | BMC Research Notes

Fig. 2

From: Combination therapy involving radiofrequency ablation and targeted chemotherapy with bevacizumab plus paclitaxel and cisplatin in a rabbit VX2 lung tumor model

Fig. 2

Survival times of the CDDP/PTX/BCM and RFA/CDDP/PTX/BCM groups are significantly prolonged compared to that of the control group. The CDDP/PTX/BCM group does not show significant differences in survival compared to the RFA alone group and the CDDP/PTX group. Survival of the RFA/CDDP/PTX group is significantly prolonged compared to that of the CDDP/PTX/BCM group. The survival time of the RFA/CDDP/PTX/BCM group is not significantly different from that of the RFA alone, and CDDP/PTX/BCM groups, but it is significantly shorter than that of the RFA/CDDP/PTX group

Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us